(Q39259470)

English

IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

triple-negative breast cancer

1 reference

based on heuristic

inferred from title

author name string

María P Roberti

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Yamila S Rocca

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Mora Amat

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

María B Pampena

4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

José Loza

5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Federico Coló

6

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Verónica Fabiano

7

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Carlos M Loza

8

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Juan M Arriaga

9

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Michele Bianchini

10

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

María M Barrio

11

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Alicia I Bravo

12

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Enzo Domenichini

13

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Reinaldo Chacón

14

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

José Mordoh

15

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Estrella M Levy

16

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

language of work or name

0 references

publication date

14 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

136

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

659-671

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

https://scigraph.springernature.com/pub.10.1007/s10549-012-2287-y

0 references

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Deconstructing the molecular portraits of breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Triple-negative breast cancers: unique clinical presentations and outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Triple-negative breast cancer: disease entity or title of convenience?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Functions of natural killer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Signal transduction during natural killer cell activation: inside the mind of a killer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Human NK cell education by inhibitory receptors for MHC class I.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

A potential role for interleukin-15 in the regulation of human natural killer cell survival

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Interleukin-2 and interleukin-15: immunotherapy for cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Modulation of tumor immunity by therapeutic monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Mechanisms of killing by anti-CD20 monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Stromal gene expression predicts clinical outcome in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2287-Y

21 January 2018

Identifiers

10.1007/S10549-012-2287-Y

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

release_u4lhaltnzvdsxnnburk2beazmi

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39259470&oldid=1816120441"